Abstract
Insulin-like growth factor 1 (IGF1) promotes cell cycle progression and inhibition of apoptosis and may have a role in carcinogenesis and cancer promotion. Growth hormone (GH) stimulates IGF1 production in liver and other tissues. The aim of our study was to evaluate differences between healthy subjects and patients with lung cancer in the GH-IGF1 axis function. In 11 healthy male patients (mean age ± standard error [SE], 43.6 ± 1.7), and 9 male patients with nonsmall-cell lung cancer (mean age ± SE, 51.0 ± 2.4), GH, total IGF1, melatonin, and interleukin (IL)-2 serum levels were measured in blood samples collected every 4 hours for 24 hours. A clear circadian rhythm was present for melatonin and GH serum levels in the group of healthy subjects and for melatonin in the group of patients with cancer. The midline estimating statistic of rhythm (MESOR) of GH was higher in patients with lung cancer (P
| Original language | English |
|---|---|
| Pages (from-to) | 68-74 |
| Number of pages | 7 |
| Journal | Clinical Lung Cancer |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2012 |
Fingerprint
Keywords
- Circadian rhythmicity
- GH
- IGF1
- IL-2
- Lung cancer
- Melatonin
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
Circadian aspects of growth hormoneinsulin-like growth factor axis function in patients with lung cancer. / Mazzoccoli, Gianluigi; Sothern, Robert B.; Pazienza, Valerio; Piepoli, Ada; Muscarella, Lucia Anna; Giuliani, Francesco; Tarquini, Roberto.
In: Clinical Lung Cancer, Vol. 13, No. 1, 01.2012, p. 68-74.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Circadian aspects of growth hormoneinsulin-like growth factor axis function in patients with lung cancer
AU - Mazzoccoli, Gianluigi
AU - Sothern, Robert B.
AU - Pazienza, Valerio
AU - Piepoli, Ada
AU - Muscarella, Lucia Anna
AU - Giuliani, Francesco
AU - Tarquini, Roberto
PY - 2012/1
Y1 - 2012/1
N2 - Insulin-like growth factor 1 (IGF1) promotes cell cycle progression and inhibition of apoptosis and may have a role in carcinogenesis and cancer promotion. Growth hormone (GH) stimulates IGF1 production in liver and other tissues. The aim of our study was to evaluate differences between healthy subjects and patients with lung cancer in the GH-IGF1 axis function. In 11 healthy male patients (mean age ± standard error [SE], 43.6 ± 1.7), and 9 male patients with nonsmall-cell lung cancer (mean age ± SE, 51.0 ± 2.4), GH, total IGF1, melatonin, and interleukin (IL)-2 serum levels were measured in blood samples collected every 4 hours for 24 hours. A clear circadian rhythm was present for melatonin and GH serum levels in the group of healthy subjects and for melatonin in the group of patients with cancer. The midline estimating statistic of rhythm (MESOR) of GH was higher in patients with lung cancer (P
AB - Insulin-like growth factor 1 (IGF1) promotes cell cycle progression and inhibition of apoptosis and may have a role in carcinogenesis and cancer promotion. Growth hormone (GH) stimulates IGF1 production in liver and other tissues. The aim of our study was to evaluate differences between healthy subjects and patients with lung cancer in the GH-IGF1 axis function. In 11 healthy male patients (mean age ± standard error [SE], 43.6 ± 1.7), and 9 male patients with nonsmall-cell lung cancer (mean age ± SE, 51.0 ± 2.4), GH, total IGF1, melatonin, and interleukin (IL)-2 serum levels were measured in blood samples collected every 4 hours for 24 hours. A clear circadian rhythm was present for melatonin and GH serum levels in the group of healthy subjects and for melatonin in the group of patients with cancer. The midline estimating statistic of rhythm (MESOR) of GH was higher in patients with lung cancer (P
KW - Circadian rhythmicity
KW - GH
KW - IGF1
KW - IL-2
KW - Lung cancer
KW - Melatonin
UR - http://www.scopus.com/inward/record.url?scp=84855692714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855692714&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2011.03.034
DO - 10.1016/j.cllc.2011.03.034
M3 - Article
VL - 13
SP - 68
EP - 74
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
SN - 1525-7304
IS - 1
ER -